Previous 10 | Next 10 |
home / stock / dskyf / dskyf news
Growth stocks continued to trail value through challenging macro and market conditions but the magnitude of underperformance has been narrowing, supporting Strategy results. To manage through the myriad uncertainties in the current environment, we continue to rely on secular and struc...
Growth stocks continued to trail value through challenging macro and market conditions but the magnitude of underperformance has been narrowing, supporting Strategy results. To manage through the myriad uncertainties in the current environment, we continue to rely on secular and struc...
At the ASCO meeting, BioNTech presented phase-1 clinical trial data for its mRNA-based vaccine for pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer. AstraZeneca and Daiichi presented data for the Destiny-Breast04 trial, which tested Enhertu against chemother...
The 2022 American Society of Clinical Oncology Annual Meeting that begins June 3 is perhaps is the most eagerly anticipated medical meeting of the year. Thousands of abstracts and studies will be presented from pharma and biotech companies large and small. Some of the results are ea...
The U.S. Food and Drug Administration (FDA) approved AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo's (OTCPK:DSKYF) (OTCPK:DSNKY) Enhertu to treat certain patients with breast cancer. Enhertu (fam-trastuzumab deruxtecan-nxki) can now be used to treat adult patients with unresectable or...
Daiichi Sankyo Company, Limited (DSKYF) Q4 2021 Results Conference Call April 27, 2022 03:30 AM ET Company Participants Hiroyuki Okuzawa - Head of Corporate Planning & Management Division, CFO Wataru Takasaki - Executive Officer, Head of R&D Division Sunao Manabe - Representative Dire...
Daiichi Sankyo Co. press release (OTCPK:DSKYF): FY GAAP EPS of ¥34.91. Revenue of ¥1.04B (+8.1% Y/Y). For further details see: Daiichi Sankyo Co. GAAP EPS of ¥34.91, revenue of ¥1.04B
The Food and Drug Administration (FDA) granted breakthrough therapy designation to AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo's (OTCPK:DSKYF) (OTCPK:DSNKY) Enhertu to treat certain patients with breast cancer. The FDA status for Enhertu is to treat adult patients with unresect...
The U.S. Food and Drug Administration (FDA) granted priority review to AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo's (OTCPK:DSKYF) (OTCPK:DSNKY) Enhertu to treat adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have a HER2 (ERBB2) mutati...
Japan has scrapped the acquisition of 40M doses of AstraZeneca's (NASDAQ:AZN) COVID vaccines, Reuters reported citing a health ministry official who spoke in the parliament. Japan had initially agreed to purchase 120M doses, with the majority made locally by Daiichi Sankyo (OTCPK:DSKYF) ...
News, Short Squeeze, Breakout and More Instantly...
Daiichi Sankyo Co Ltd Company Name:
DSKYF Stock Symbol:
OTCMKTS Market:
Publication highlights Europe -specific one-year follow-up findings for atrial fibrillation (AF) patients in routine clinical practice, in which, rates of stroke, systemic embolism, and major bleeding are considered by the authors to be low in edoxaban treated patients [1] Findings...
· Results published in the European Heart Journal – Cardiovascular Pharmacotherapy , showed rates of thromboembolism similar to those observed in the ENGAGE AF-TIMI 48 clinical trial [1] · Study reports LIXIANA outcomes from one of the largest observational ...
- ENTRUST-AF PCI study achieved the primary safety endpoint of non-inferiority in bleeding for edoxaban-based dual therapy compared with VKA-based triple antithrombotic therapy (using a risk-based duration of ASA for at least one month) in AF patients following stent placement - ...